Events Partner Content 3rd Chronic Kidney Disease Drug Development (CKD3) Summit Advance Therapeutics for Chronic Kidney Diseases
Events Partner Content 3rd Chronic Kidney Disease Drug Development (CKD3) Summit Advance Therapeutics for Chronic Kidney Disease
News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.